Neurosense Therapeutics is trading 8.46% up at $0.48 after its August 13, 2026 CEO letter detailed delays securing funding for the Phase 3 PARAGON ALS study. - The company is pursuing pharmaceutical partners, investors, grants, and other financing sources. - The letter highlighted Nasdaq compliance concerns and a potential 1-for-4 to 1-for-40 reverse split authorization. - Regular-session shares closed at $0.44, down 5.46%.